DekaBank Deutsche Girozentrale
GLUE icon

DekaBank Deutsche Girozentrale’s Monte Rosa Therapeutics GLUE Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-16,500
Closed -$121K – 1323
2022
Q4 		$121K Hold
16,500
– – ﹤0.01% 1274
2022
Q3 		$131K Hold
16,500
– – ﹤0.01% 1280
2022
Q2 		$162K Buy
+16,500
New +$166K ﹤0.01% 1225
2022
Q1 		– Sell
-15,000
Closed -$293K – 1375
2021
Q4 		$293K Buy
+15,000
New +$314K ﹤0.01% 1200

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DekaBank Deutsche Girozentrale's GLUE Position: Q1 2023 in Review

DekaBank Deutsche Girozentrale sold out of Monte Rosa Therapeutics (GLUE) in Q1 2023, closing a stake of 16,500 shares — an estimated $121K sold.

DekaBank Deutsche Girozentrale first reported a position in GLUE in Q4 2021 and held it in 4 quarters. The position peaked at $293K in Q4 2021. 69 funds tracked by Wall St. Rank hold GLUE as of Q1 2023.

  • DekaBank Deutsche Girozentrale reported no remaining Monte Rosa Therapeutics position as of Q1 2023 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 16,500 Monte Rosa Therapeutics shares in Q1 2023, an estimated $121K.
  • DekaBank Deutsche Girozentrale first reported a position in Monte Rosa Therapeutics in Q4 2021 and held it in 4 quarters.
  • DekaBank Deutsche Girozentrale's Monte Rosa Therapeutics position peaked at $293K in Q4 2021.
  • 69 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2023.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q1 2023, filed 24 Apr 2023.